Radiopharm Theranostics (RAD) Short Interest
Radiopharm Theranostics (ASX:RAD) had 0.02% of shares reported as short positions as of 3 Aug 2026, representing 875,237 shares. Radiopharm Theranostics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage radiotherapeutics company focused on developing a pipeline of first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer. The company aims to transform cancer care by delivering innovative solutions for earlier detection and personalized treatment of cancers with unmet needs.
Short position
Radiopharm Theranostics (ASX:RAD) has 0.02% of its shares on issue reported as short positions as of 3 Aug 2026, or about 875,237 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.27% in June 2024. RAD is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4RAD intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Radiopharm Theranostics
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss RAD
Start a research thread or post the first pulse update